chartexchange

Zura Bio Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Zura Bio Limited (ZURA)

PR Newswire | Nov 9, 2026 5:35 PM EST

Zura Bio's October 27, 2026 SEC filing, which included a shelf registration covering up to $700 million in securities, described tibulizumab as the Company's lead product candidate being "currently advanced" in Phase 2 clinical trials. Less than two weeks later, TibuSHIELD failed to meet...

Read original article